search
Back to results

Vitamin D, C-reactive Protein and Insulin Resistance

Primary Purpose

Diabetes, Low-intensity Chronic Inflammation, Insulin Resistance

Status
Completed
Phase
Phase 3
Locations
Mexico
Study Type
Interventional
Intervention
cholecalciferol
placebo
Sponsored by
Instituto Nacional de Salud Publica, Mexico
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes focused on measuring vitamin D, diabetes, C-reactive protein, insulin resistance

Eligibility Criteria

45 Years - 65 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Type 2 diabetes mellitus w/ < 10 yrs of diagnosis
  • Postmenopausal
  • Overweight or obesity (BMI >=25)
  • Treated with metformin

Exclusion Criteria:

  • BMI >=40
  • Liver or kidney disease
  • Other important chronic disease: i.e. cancer, autoimmune.
  • Receiving insulin

Sites / Locations

  • Instituto Mexicano del Seguro Social

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Vitamin D

Placebo

Arm Description

Cholecalciferol, 4,000 IU/d for 6 months

placebo

Outcomes

Primary Outcome Measures

Serum C-reactive protein concentrations, measured by a high-sensitivity assay -nephelometry-.
Insulin resistance, measured by HOMA-IR index

Secondary Outcome Measures

Serum 25-OH-vitamin D3 levels

Full Information

First Posted
November 23, 2009
Last Updated
November 23, 2009
Sponsor
Instituto Nacional de Salud Publica, Mexico
Collaborators
Instituto Mexicano del Seguro Social, Ellison Medical / International Nutrition Foundation, Tufts University
search

1. Study Identification

Unique Protocol Identification Number
NCT01019642
Brief Title
Vitamin D, C-reactive Protein and Insulin Resistance
Official Title
Effect of Vitamin D Supplementation on C-reactive Protein and Insulin Resistance in Postmenopausal Women With Type 2 Diabetes Mellitus
Study Type
Interventional

2. Study Status

Record Verification Date
November 2009
Overall Recruitment Status
Completed
Study Start Date
March 2008 (undefined)
Primary Completion Date
October 2008 (Actual)
Study Completion Date
October 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Instituto Nacional de Salud Publica, Mexico
Collaborators
Instituto Mexicano del Seguro Social, Ellison Medical / International Nutrition Foundation, Tufts University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Randomized, double blind, placebo-controlled clinical trial of vitamin D supplementation (cholecalciferol, 4,000 IU/day for 6 months, in 104 postmenopausal women with type 2 diabetes mellitus. The objective was to evaluate the effect of vitamin D supplementation on C-reactive protein (CRP) and insulin resistance in women with type 2 diabetes mellitus (T2DM). The trial was conducted from March to October 2008 at the Hospital of the Mexican Social Security in Cuernavaca, Mexico.
Detailed Description
Methods. Randomized, double blind, placebo-controlled clinical trial. We selected 104 postmenopausal women, ages 45 to 65, with uncomplicated T2DM and BMI ≥25. Women with history of kidney or liver disease, BMI>40, autoimmune disease or cancer were not included in the study. Participants were randomly assigned to receive either a capsule containing 4,000 IU of vitamin D3 (cholecalciferol, n=52) or placebo (n=52), once a day during 6 months. Outcome variables were serum CRP, measured with a high-sensitivity assay (nephelometry), and HOMA-IR. Serum vitamin D (25-OH-D) was measured by HPLC. Outcome variables were measured at baseline, and 3 and 6 months thereafter. All participants received diet and physical activity counseling, and visited the clinic for medical check-up once a month. Baseline Results. Mean age was 56.8 ± 5.1 y. Baseline BMI was 30.7 ± 3.9. Median CRP concentration was 5.0 mg/L (Interquartile range: 1.0, 8.5). HOMA index at baseline was 7.13 ± 3.8. Serum 25-OH-D concentration at baseline was 54.5 ± 15.7 nmol/L (~22 ng/mL). Almost 94% of patients had baseline serum 25-OH-D levels <80 nmol/L, and 25% were below 40 nmol/L. No one had levels <20 nmol/L. There were no statistical differences on important variables by treatment group at the onset of study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes, Low-intensity Chronic Inflammation, Insulin Resistance
Keywords
vitamin D, diabetes, C-reactive protein, insulin resistance

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
104 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Vitamin D
Arm Type
Experimental
Arm Description
Cholecalciferol, 4,000 IU/d for 6 months
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
placebo
Intervention Type
Drug
Intervention Name(s)
cholecalciferol
Intervention Description
4,000 IU per day during 6 months. Capsule form.
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
no active principles given.
Primary Outcome Measure Information:
Title
Serum C-reactive protein concentrations, measured by a high-sensitivity assay -nephelometry-.
Time Frame
3 and 6 months
Title
Insulin resistance, measured by HOMA-IR index
Time Frame
3 and 6 months
Secondary Outcome Measure Information:
Title
Serum 25-OH-vitamin D3 levels
Time Frame
3 and 6 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Type 2 diabetes mellitus w/ < 10 yrs of diagnosis Postmenopausal Overweight or obesity (BMI >=25) Treated with metformin Exclusion Criteria: BMI >=40 Liver or kidney disease Other important chronic disease: i.e. cancer, autoimmune. Receiving insulin
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mario E Flores, MD, MSc
Organizational Affiliation
Instituto Nacional de Salud Publica, Mexico
Official's Role
Principal Investigator
Facility Information:
Facility Name
Instituto Mexicano del Seguro Social
City
Cuernavaca
State/Province
Morelos
ZIP/Postal Code
62450
Country
Mexico

12. IPD Sharing Statement

Citations:
PubMed Identifier
19079903
Citation
Flores M. A role of vitamin D in low-intensity chronic inflammation and insulin resistance in type 2 diabetes mellitus? Nutr Res Rev. 2005 Dec;18(2):175-82. doi: 10.1079/NRR2005104.
Results Reference
background
PubMed Identifier
25453396
Citation
Munoz-Aguirre P, Flores M, Macias N, Quezada AD, Denova-Gutierrez E, Salmeron J. The effect of vitamin D supplementation on serum lipids in postmenopausal women with diabetes: A randomized controlled trial. Clin Nutr. 2015 Oct;34(5):799-804. doi: 10.1016/j.clnu.2014.10.002. Epub 2014 Oct 13.
Results Reference
derived

Learn more about this trial

Vitamin D, C-reactive Protein and Insulin Resistance

We'll reach out to this number within 24 hrs